KR900017610A - Method for preparing a tumor suppressor pharmaceutical composition containing gonadolibrine derivatives - Google Patents

Method for preparing a tumor suppressor pharmaceutical composition containing gonadolibrine derivatives Download PDF

Info

Publication number
KR900017610A
KR900017610A KR1019890006230A KR890006230A KR900017610A KR 900017610 A KR900017610 A KR 900017610A KR 1019890006230 A KR1019890006230 A KR 1019890006230A KR 890006230 A KR890006230 A KR 890006230A KR 900017610 A KR900017610 A KR 900017610A
Authority
KR
South Korea
Prior art keywords
group
amino acid
alkyl
amide
gonadolibrine
Prior art date
Application number
KR1019890006230A
Other languages
Korean (ko)
Inventor
케리 게오르기
아이. 니콜슨 로버트
테플란 이스트반
걸리아스 타마스
호르바스 아니코
보코니 니 마조르 게오르기
스죠크 발라즈스
발로그 아그네스
츠우카 올솔리아
Original Assignee
카롤리 체더, 카롤리 메턱
이노피낸스 알탈라노스 이노바씨오스 펜진테제트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카롤리 체더, 카롤리 메턱, 이노피낸스 알탈라노스 이노바씨오스 펜진테제트 filed Critical 카롤리 체더, 카롤리 메턱
Publication of KR900017610A publication Critical patent/KR900017610A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)

Abstract

내용 없음No content

Description

고나돌리베린 유도체를 함유하는 종양억제용 약제조성물의 제조방법Method for preparing a tumor suppressor pharmaceutical composition containing gonadolibrine derivatives

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (4)

다음 일반식(I)로 표시되는 고나돌리베린 유도체 또는 그의 약제학적으로 허용가능한 산첨가 염 또는 금속 착물을 함유하는 약제조성물을 제조함에 있어서, 다음 일반식(I)의 고나돌리베린 유도체 또는 공지 방법으로 제조된 산첨가 염 또는 금속착물을 제약산업분야에서 통상적으로 사용되는 담체, 첨가제 또는 담체 및 첨가제와 혼합시킨 다음, 어떠한 호르몬의 제거를 야기시키지 않고서 호르몬 의존성 종양의 치료에 효과적인 약제조성물로 전환시킴을 특징으로 하는 다음 일반식(I)로 표시되는 고나돌리베린 유도체 또는 그의 약제학적으로 허용가능한 산첨가 염 또는 금속착물을 함유하는 약제조성물의 제조방법.In preparing a pharmaceutical composition containing a gonadolibrine derivative represented by the following general formula (I) or a pharmaceutically acceptable acid addition salt or a metal complex thereof, the gonadolibrine derivative or the known method of the following general formula (I) Acid salts or metal complexes prepared in the present invention are mixed with carriers, additives or carriers and additives commonly used in the pharmaceutical industry, and then converted into pharmaceutical compositions effective for the treatment of hormone-dependent tumors without causing any hormones to be removed. A method for producing a pharmaceutical composition containing a gonadolibrine derivative represented by the following general formula (I) or a pharmaceutically acceptable acid addition salt or metal complex thereof Glp-His-Trp-Ser-Yyr-X1-X2-X3-Pro-X4(I)Glp-His-Trp-Ser-Yyr-X 1 -X 2 -X 3 -Pro-X 4 (I) 상기식에서, X1은 글리실기이거나 또는 어떠한 천연 또는 합성 또는 합성의 방향족 D-아미노산기의 D-이성질체이고; X2는 C1-4알킬기, L-페닐알라닐기 또는 L-트립토필기를 포함하는 L-아미노산기이고; X3는 C1-4알킬 또는 C2-4알카노일 아미드측쇄를 포함하는 L-아미노산 잔기이며; 그리고 X4는글리시딜 아미드 또는 C1-4알킬 아미드기로서, 여기서, X2가 트립토필이고 동시에 X1이 글리실기가 아닌 경우에는 X3는 루이실기가 아니다.Wherein X 1 is a glycyl group or a D-isomer of any natural or synthetic or synthetic aromatic D-amino acid group; X 2 is an L-amino acid group comprising a C 1-4 alkyl group, L-phenylalanyl group or L-tryptophil group; X 3 is an L-amino acid residue comprising a C 1-4 alkyl or C 2-4 alkanoyl amide side chain; And X 4 is a glycidyl amide or C 1-4 alkyl amide group wherein X 3 is not a louisyl group when X 2 is a tryptophil and at the same time X 1 is not a glycyl group. 제1항에 있어서, 상기 약제조성물은 1회 투약량중에, 상기 일반식(I)로 표시되는 화합물의 함량이 0.0035∼350㎍이 되도록 조제함을 특징으로 하는 약제 조성물의 제조방법.The method of claim 1, wherein the pharmaceutical composition is prepared in a single dosage so that the content of the compound represented by the general formula (I) is 0.0035 to 350 µg. 다음 일반식(I)로 표시되는 고나돌리베린 유도체를 사용한 종양 및 그의 임상 상태의 치료용 약제조성물.A pharmaceutical composition for the treatment of a tumor and its clinical condition using a gonadolibrine derivative represented by the following general formula (I). Glp-His-Trp-Ser-X1-X2-X3Pro-X4(I)Glp-His-Trp-Ser-X 1 -X 2 -X 3 Pro-X 4 (I) 상기식에서, X1은 글리실기이거나 또는 어떠한 천연 또는 합성 또는 합성의 방향족 D-아미노산기의 D-이성질체이고; X2는 C1-4알킬기, L-페닐알라닐기 또는 L-트립토필기를 포함하는 L-아미노산기이고; X3는 C1-4알킬 또는 C2-4알키노일 아미드측쇄를 포함하는 L-아미노산 잔기이며; 그리고 X4는글리시딜 아미드 또는 C1-4알킬 아미드기로서, 여기서, X2가 트립토필이고 동시에 X1이 글리실기가 아닌 경우에는 X3는 루이실기가 아니다.Wherein X 1 is a glycyl group or a D-isomer of any natural or synthetic or synthetic aromatic D-amino acid group; X 2 is an L-amino acid group comprising a C 1-4 alkyl group, L-phenylalanyl group or L-tryptophil group; X 3 is an L-amino acid residue comprising a C 1-4 alkyl or C 2-4 alkinoyl amide side chain; And X 4 is a glycidyl amide or C 1-4 alkyl amide group wherein X 3 is not a louisyl group when X 2 is a tryptophil and at the same time X 1 is not a glycyl group. 다음 일반식(I)로 표시되는 고나돌리베린 유도체를 사용한 종양 및 그의 임상상태 치료제.Glp-His-Trp-Ser-Tyr-X1-X2-X3-Pro-X4(I)A therapeutic agent for a tumor and its clinical condition using a gonadolibrine derivative represented by the following general formula (I): Glp-His-Trp-Ser-Tyr-X 1 -X 2 -X 3 -Pro-X 4 (I) 상기식에서, X1은 글리실기이거나 또는 어떠한 천연 또는 합성 또는 합성의 방향족 D-아미노산기의 D-이성질체이고; X2는 C1-4알킬기, L-페닐알라닐기 또는 L-트립토필기를 포함하는 L-아미노산기이고; X3는 C1-4알킬 또는 C2-4알키노일 아미드측쇄를 포함하는 L-아미노산 잔기이며; 그리고 X4는글리시딜 아미드 또는 C1-4알킬 아미드기로서, 여기서, X2가 트립토필이고 동시에 X1이 글리실기가 아닌 경우에는 X3는 루이실기가 아니다.Wherein X 1 is a glycyl group or a D-isomer of any natural or synthetic or synthetic aromatic D-amino acid group; X 2 is a C1 -4 alkyl group, L- Ala phenyl group or L- trip Sat handwriting L- amino acid group containing gt; X 3 is an L-amino acid residue comprising a C 1-4 alkyl or C 2-4 alkinoyl amide side chain; And X 4 is a glycidyl amide or C 1-4 alkyl amide group wherein X 3 is not a louisyl group when X 2 is a tryptophil and at the same time X 1 is not a glycyl group. ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019890006230A 1988-05-10 1989-05-10 Method for preparing a tumor suppressor pharmaceutical composition containing gonadolibrine derivatives KR900017610A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU2347/88 1988-05-10
HU882347A HU199694B (en) 1988-05-10 1988-05-10 Process for producing citostatic pharmaceutical compositions containing gonadoliberin derivatives

Publications (1)

Publication Number Publication Date
KR900017610A true KR900017610A (en) 1990-12-19

Family

ID=10958948

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890006230A KR900017610A (en) 1988-05-10 1989-05-10 Method for preparing a tumor suppressor pharmaceutical composition containing gonadolibrine derivatives

Country Status (16)

Country Link
JP (1) JPH0215097A (en)
KR (1) KR900017610A (en)
BE (1) BE1004932A3 (en)
CH (1) CH678013A5 (en)
DE (1) DE3915317A1 (en)
DK (1) DK228289A (en)
FI (1) FI892275A (en)
FR (1) FR2631237A1 (en)
GB (1) GB2218335B (en)
GR (1) GR890100315A (en)
HU (1) HU199694B (en)
IL (1) IL89998A0 (en)
IT (1) IT1229251B (en)
LU (1) LU87516A1 (en)
NL (1) NL8901159A (en)
SE (1) SE8901660L (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760000A (en) * 1994-05-13 1998-06-02 University Technologies International,Inc. Inhibition of liver cancer by the use of GnRH and GnRH analogs
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4410514A (en) * 1982-12-06 1983-10-18 The Salk Institute For Biological Studies GnRH Agonists
IT1178775B (en) * 1983-12-23 1987-09-16 Konzponti Valto Es Hitelbank R GONADOLIBERINE DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION
HU189394B (en) * 1983-12-23 1986-06-30 Koezponti Valto- Es Hitelbank Rt Innovacios Alap,Hu Method for producing spermatozoa suitable for fertilization from mature fishes
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
ATE75947T1 (en) * 1984-08-02 1992-05-15 Labrie Fernand PHARMACEUTICAL COMPOSITION FOR COMBINATION THERAPY OF HORMONAL DEPENDENT CANCER.
HU193607B (en) * 1985-07-18 1987-11-30 Innofinance Altalanos Innovaci Process for production of sexual products applyable for natural or artificial insemination for mammates
US4721775A (en) * 1985-08-26 1988-01-26 Board Of Regents, The University Of Texas System Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids
HU194913B (en) * 1986-01-03 1988-03-28 Innofinance Altalanos Innovaci Process for producing novel gonadoliberin derivatives containing in the sixth position aromatic amino carboxylic acid and medical preparations containing these compounds

Also Published As

Publication number Publication date
HUT49813A (en) 1989-11-28
SE8901660D0 (en) 1989-05-10
DK228289A (en) 1989-11-11
DK228289D0 (en) 1989-05-10
GB2218335B (en) 1991-09-25
LU87516A1 (en) 1990-12-11
JPH0215097A (en) 1990-01-18
BE1004932A3 (en) 1993-03-02
NL8901159A (en) 1989-12-01
FI892275A (en) 1989-11-11
IT8920435A0 (en) 1989-05-11
HU199694B (en) 1990-03-28
IT1229251B (en) 1991-07-26
DE3915317A1 (en) 1989-11-23
FI892275A0 (en) 1989-05-10
GB2218335A (en) 1989-11-15
IL89998A0 (en) 1989-12-15
GB8910724D0 (en) 1989-06-28
GR890100315A (en) 1990-03-12
CH678013A5 (en) 1991-07-31
SE8901660L (en) 1989-11-11
FR2631237A1 (en) 1989-11-17

Similar Documents

Publication Publication Date Title
KR880011199A (en) Novel peptide compounds, methods for their preparation and pharmaceutical compositions containing them
KR900007837A (en) Quinuclidin, its use as a medicament and method for preparing the same
HUP9902121A2 (en) Indole derivatives as antagonists of gonadotropin releasing hormone and pharmaceutical compositions containing them
KR870003974A (en) Bicyclo substituted phenylacetonitrile derivatives
GB940596A (en) ª -hydrazino acids
KR950701646A (en) Polypeptide Bombesin Antagonist (POLYPEPTIDE BOMBESTN ANTAGONISIS)
KR970061246A (en) Pharmaceutical Compositions for Increasing Testosterone
KR890014107A (en) Platinum Chemotherapy
KR900014406A (en) Cefem compound and preparation method thereof
KR900700098A (en) Plaboxate and its derivatives for the treatment and diagnosis of erectile dysfunction
KR930700502A (en) 6-aminooctahydroindolizintriol derivatives
KR900017610A (en) Method for preparing a tumor suppressor pharmaceutical composition containing gonadolibrine derivatives
KR880000461A (en) Androst-4-ene-3,17-dione and preparation method thereof
KR900014385A (en) Pharmaceutical treatment
KR900014397A (en) Thieno-triazolo-diazepine sulfonyl derivatives, methods for their preparation and therapeutic compositions containing them
GB1415471A (en) Phenylethylamine derivatives
HRP20000733B1 (en) NOVEL OCTAHYDRO-6,10-DIOXO-6H-PYRIDAZINO/1,2-a/ /1,2/DIAZEPIN-1-CARBOXYLIC ACID DERIVATIVES, PREPARATION METHOD AND USE FOR PREPARING THERAPEUTICALLY ACTIVE COMPOUNDS
GB1493684A (en) S-substituted-2-thiodenosines
KR890003368A (en) How to treat nausea and vomiting with certain substituted phenylalkylamino (and amino acid) derivatives and other serotonin-lowering agents
KR910002792A (en) 1-Substituted-2- (3-amino-1-propynyl) pyrrolidine derivatives, thereby methods for treating central cholinergic dysfunction and pharmaceutical compositions thereof
KR900017581A (en) Peptide-Pharmaceutical Compositions Containing α-Aminoboronic Acid Derivatives
KR890012960A (en) Crystalline β-lactam Solvate
KR950702830A (en) METHODS OF TREATING PSORIASIS EMPLOYING SUBSTITUTED AZASPIRANES
KR880013896A (en) Benzofuro [3,2-C] quinoline compound
KR890003762A (en) Polyhydro Derivatives of 10.11-dihydro-5H-dibenzo [a, d] cyclohepten-5,10-imine

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid